Camilla Evangelisti

List of Publications by Year
in descending order

81 papers	8,092 citations	81900 39 h-index	66911 78 g-index
82 all docs	82 docs citations	82 times ranked	12899 citing authors

#	Article	IF	Citations
1	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1263-1284.	4.1	1,858
2	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging, 2011, 3, 192-222.	3.1	520
3	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. Oncotarget, 2011, 2, 135-164.	1.8	509
4	Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia, 2006, 20, 911-928.	7.2	295
5	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget, 2012, 3, 1068-1111.	1.8	279
6	Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.. Oncotarget, 2012, 3, 954-987.	1.8	244
7	Current treatment strategies for inhibiting mTOR in cancer. Trends in Pharmacological Sciences, 2015, 36, 124-135.	8.7	234
8	Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia, 2011, 25, 1080-1094.	7.2	232
9	The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget, 2010, 1, 89-103.	1.8	227
10	Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia, 2011, 25, 1064-1079.	7.2	190
11	Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia, 2007, 21, 427-438.	7.2	170
12	The emerging multiple roles of nuclear Akt. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 2168-2178.	4.1	165
13	Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia. Cancer Research, 2010, 70, 8097-8107.	0.9	152
14	Intranuclear 3â€²-phosphoinositide metabolism and Akt signaling: New mechanisms for tumorigenesis and protection against apoptosis?. Cellular Signalling, 2006, 18, 1101-1107.	3.6	121
15	Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Module for Acute Myelogenous Leukemia Therapy: From Bench to Bedside. Current Medicinal Chemistry, 2007, 14, 2009-2023.	2.4	116
16	Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cells. Current Medicinal Chemistry, 2011, 18, 2715-2726.	2.4	109
17	Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget, 2012, 3, 371-394.	1.8	109
18	The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2010, 1803, 991-1002.	4.1	106

#	Article	IF	Citations
19	Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia, 2008, 22, 147-160.	7.2	105
20	Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opinion on Investigational Drugs, 2009, 18, 1333-1349.	4.1	104
21	Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 449-463.	4.1	104
22	Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia, 2011, 25, 781-791.	7.2	91
23	Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells. Cancer Research, 2008, 68, 9394-9403.	0.9	84
24	The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia, 2007, 21, 886-896.	7.2	81
25	Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance. Advances in Enzyme Regulation, 2007, 47, 64-103.	2.6	77
26	Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia, 2012, 26, 2336-2342.	7.2	76
27	Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling. Leukemia, 2014, 28, 543-553.	7.2	74
28	Autophagy in acute leukemias: A double-edged sword with important therapeutic implications. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 14-26.	4.1	74
29	Therapeutic targeting of CK2 in acute and chronic leukemias. Leukemia, 2018, 32, 1-10.	7.2	74
30	Nuclear protein kinase C. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2006, 1761, 542-551.	2.4	72
31	Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia, 2008, 22, 2080-2090.	7.2	70
32	Preclinical testing of the Akt inhibitor triciribine in Tâ€cell acute lymphoblastic leukemia. Journal of Cellular Physiology, 2011, 226, 822-831.	4.1	59
33	Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels. Oncotarget, 2012, 3, 811-823.	1.8	58
34	Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeriaâ€related disorders. British Journal of Clinical Pharmacology, 2016, 82, 1229-1244.	2.4	47
35	Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. Journal of Hematology and Oncology, 2016, 9, 114.	17.0	47
36	Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias. British Journal of Haematology, 2005, 130, 716-725.	2.5	43

#	Article	IF	Citations
37	Nuclear diacylglycerol kinaseâ€Î¶ is a negative regulator of cell cycle progression in C2C12 mouse myoblasts. FASEB Journal, 2007, 21, 3297-3307.	0.5	41
38	Advances in Targeting Signal Transduction Pathways. Oncotarget, 2012, 3, 1505-1521.	1.8	41
39	The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology. Cancers, 2010, 2, 1576-1596.	3.7	40
40	Targeting Wnt/Î²â€catenin and PI3K/Akt/mTOR pathways in Tâ€cell acute lymphoblastic leukemia. Journal of Cellular Physiology, 2020, 235, 5413-5428.	4.1	40
41	Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy. Current Pharmaceutical Design, 2012, 18, 1784-1795.	1.9	39
42	Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-ÎºB. Oncotarget, 2016, 7, 1323-1340.	1.8	39
43	The Role Played by Wnt/Î²-Catenin Signaling Pathway in Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences, 2020, 21, 1098.	4.1	38
44	Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. Expert Opinion on Therapeutic Targets, 2012, 16, 729-742.	3.4	37
45	Nuclear inositol lipid metabolism: More than just second messenger generation?. Journal of Cellular Biochemistry, 2005, 96, 285-292.	2.6	36
46	Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. Oncotarget, 2014, 5, 7886-7901.	1.8	36
47	Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. Leukemia, 2010, 24, 687-698.	7.2	34
48	Targeting Signaling Pathways in T-cell acute lymphoblastic leukemia initiating cells. Advances in Biological Regulation, 2014, 56, 6-21.	2.3	34
49	Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. Leukemia, 2016, 30, 2142-2151.	7.2	34
50	Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. International Journal of Molecular Sciences, 2018, 19, 1878.	4.1	34
51	Subnuclear localization and differentiation-dependent increased expression of DGK-Î¶ in C2C12 mouse myoblasts. Journal of Cellular Physiology, 2006, 209, 370-378.	4.1	33
52	PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. Oncotarget, 2015, 6, 10399-10414.	1.8	32
53	Nuclear phosphoinositides and their roles in cell biology and disease. Critical Reviews in Biochemistry and Molecular Biology, 2011, 46, 436-457.	5.2	30
54	Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. Cell Cycle, 2014, 13, 2237-2247.	2.6	30

#	Article	IF	Citations
55	The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. Histology and Histopathology, 2010, 25, 669-80.	0.7	30
56	The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias. Cancers, 2020, 12, 333.	3.7	29
57	The wide and growing range of lamin B-related diseases: from laminopathies to cancer. Cellular and Molecular Life Sciences, 2022, 79, 126.	5.4	29
58	Phosphatidylinositol 3â€kinase inhibition potentiates glucocorticoid response in Bâ€cell acute lymphoblastic leukemia. Journal of Cellular Physiology, 2018, 233, 1796-1811.	4.1	28
59	The Cutting Edge: The Role of mTOR Signaling in Laminopathies. International Journal of Molecular Sciences, 2019, 20, 847.	4.1	27
60	TIS21/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase-Î¶-dependent cell cycle arrest. Cellular Signalling, 2009, 21, 801-809.	3.6	26
61	Identification of a functional nuclear export sequence in diacyl glycerol kinase-Î¶. Cell Cycle, 2010, 9, 384-388.	2.6	26
62	Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins. Oncotarget, 2015, 6, 7424-7437.	1.8	25
63	Elevated TGF Î²2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes. Nucleus, 2018, 9, 337-349.	2.2	25
64	PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: New options for targeted therapy. Advances in Biological Regulation, 2012, 52, 214-227.	2.3	23
65	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. Advances in Enzyme Regulation, 2008, 48, 113-135.	2.6	20
66	Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review). International Journal of Oncology, 2014, 45, 909-918.	3.3	20
67	Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 1322-1337.	4.1	20
68	GSK-3: a multifaceted player in acute leukemias. Leukemia, 2021, 35, 1829-1842.	7.2	20
69	DGKÎ¶ is degraded through the cytoplasmic ubiquitinâ€“proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry. Cellular Signalling, 2012, 24, 1573-1582.	3.6	19
70	New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia. Advances in Biological Regulation, 2019, 74, 100649.	2.3	17
71	Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. Expert Opinion on Therapeutic Targets, 2013, 17, 921-936.	3.4	15
72	PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. Oncotarget, 2017, 8, 23213-23227.	1.8	15

#	Article	IF	Citations
73	Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. Advances in Biological Regulation, 2013, 53, 146-155.	2.3	14
74	Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells. Cells, 2020, 9, 774.	4.1	14
75	B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?. Cancers, 2020, 12, 3498.	3.7	11
76	GSK-3Î²: A key regulator of breast cancer drug resistance. Cell Cycle, 2014, 13, 697-698.	2.6	8
77	The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML). Current Signal Transduction Therapy, 2007, 2, 246-256.	0.5	3
78	The PI3K/Akt/mTOR Pathway. , 2016, , 128-135.		2
79	New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways. , 2013, , 331-372.		1
80	3232 Synergistic cytotoxic effects of bortezomib and ck2 inhibitor cx-4945 in acute lymphoblastic leukemia: turning off the prosurvival er chaperone BIP/GRP78 and turning on the proapoptotic NF-Îºb. European Journal of Cancer, 2015, 51, S659-S660.	2.8	1
81	Cell Communication: Intracellular Pathways â€“ The PI3K/Akt/mTOR Pathway. , 2022, , .		0